ReviewPharmacoEconomics2020
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Review in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- A Meta-Analysis of the Efficacy and Safety of the 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis.Biomedicines · 2025Article
- Use of corticosteroids in non-infectious uveitis - expert consensus in Taiwan.Annals of medicine · 2024Review
- Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology.Ophthalmology and therapy · 2022Article
- Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve.Ophthalmology and therapy · 2022Article
- Lipid Nanoparticles for the Posterior Eye Segment.Pharmaceutics · 2021Review
- [Guidelines nr. 24a intermediate uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Comment on 'Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal'.PharmacoEconomics · 2020Article
- Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".PharmacoEconomics · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.